Cencora (COR) Stock Price, News & Analysis

Company Overview

Cencora, Inc. sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers. This segment also distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; and provides other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment offers international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals primarily in Europe; and provides specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was incorporated in 2001 and is headquartered in Conshohocken, Pennsylvania.

Key Stats

• Today's Range: $240.53 to $243.64
• 50-Day Range: $219.50 to $249.95
• 52-Week Range: $195.83 to $251.56
• Volume: 753,912 shs
• Average Volume: 1.40 million shs
• Market Capitalization: $47.92 billion
• P/E Ratio: 32.38
• Dividend Yield: 0.90%
• Price Target: $271.20
• Consensus Rating: Moderate Buy

Cencora Stock Analysis - MarketRank™

Cencora scored higher than 97% of companies evaluated by MarketBeat, and ranked 44th out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Cencora has received a consensus rating of Moderate Buy. The company's average rating score is 2.73, and is based on 8 buy ratings, 3 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Cencora has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 9.11%

Earnings Growth

Earnings for Cencora are expected to grow by 9.11% in the coming year, from $14.93 to $16.29 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Cencora is 32.38, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 131.22.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cencora is 32.38, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 126.32.

Price to Earnings Growth Ratio

Cencora has a PEG Ratio of 1.60. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Cencora has a P/B Ratio of 60.95. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.65% of the float of Cencora has been sold short.

Short Interest Ratio / Days to Cover

Cencora has a short interest ratio ("days to cover") of 6.9.

Change versus previous month

Short interest in Cencora has recently increased by 3.53%, indicating that investor sentiment is decreasing.

Dividend

• Score: 3.3 / 5
• Dividend Strength: Strong

Dividend Yield

Cencora has a dividend yield of 0.92%, which is in the bottom 25% of all stocks that pay dividends.

Dividend Growth

Cencora has been increasing its dividend for 15 years.

Dividend Coverage

The dividend payout ratio of Cencora is 29.29%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Cencora will have a dividend payout ratio of 13.51% next year. This indicates that Cencora will be able to sustain or increase its dividend.

Sustainability and ESG

• Score: 3.1 / 5
• Environmental Score: -0.77

Percentage of Shares Shorted

5.65% of the float of Cencora has been sold short.

Short Interest Ratio / Days to Cover

Cencora has a short interest ratio ("days to cover") of 6.9.

Change versus previous month

Short interest in Cencora has recently increased by 3.53%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 3.4 / 5
• News Sentiment: 1.17

News Sentiment

Cencora has a news sentiment score of 1.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.45 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 20 news articles for Cencora this week, compared to 10 articles on an average week.

Search Interest

14 people have searched for COR on MarketBeat in the last 30 days. This is an increase of 250% compared to the previous 30 days.

MarketBeat Follows

Only 3 people have added Cencora to their MarketBeat watchlist in the last 30 days. This is a decrease of -57% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Cencora insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,071,822.00 in company stock.

Percentage Held by Insiders

15.80% of the stock of Cencora is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

97.52% of the stock of Cencora is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

COR Stock Analysis - Frequently Asked Questions

How have COR shares performed this year?

Cencora's stock was trading at $205.38 at the start of the year. Since then, COR stock has increased by 18.4% and is now trading at $243.20.
View the best growth stocks for 2024 here.

How were Cencora's earnings last quarter?

Cencora, Inc. (NYSE:COR) issued its quarterly earnings data on Wednesday, July, 31st. The company reported $3.34 earnings per share for the quarter, topping analysts' consensus estimates of $3.18 by $0.16. The firm's quarterly revenue was up 10.8% compared to the same quarter last year.

Does Cencora have any subsidiaries?

Cencora subsidiaries include Alliance Healthcare, H. D. Smith, St. Francis Group, PharMEDium Healthcare, MWI Veterinary Supply, World Courier, IntrinsiQ, and more.

Who are Cencora's major shareholders?

Top institutional shareholders of Cencora include Walgreens Boots Alliance Inc. (10.14%), State Street Corp (4.08%), Wellington Management Group LLP (2.64%) and Geode Capital Management LLC (2.13%). Insiders that own company stock include Walgreens Boots Alliance, Inc, Steven H Collis, Robert P Mauch, Robert P Mauch, Dermot Mark Durcan, Lazarus Krikorian, Gina Clark, Gina Clark, Silvana Battaglia, Leslie E Donato, Leslie E Donato and Elizabeth S Campbell.
View institutional ownership trends.

How do I buy shares of Cencora?

Shares of COR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Cencora own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Cencora investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Broadcom (AVGO), Netflix (NFLX) and Tesla (TSLA).

Company Calendar

• Last Earnings: 7/31/2024
• Ex-Dividend for 8/26 Dividend: 8/09/2024
• Dividend Payable: 8/26/2024
• Ex-Dividend for 11/29 Dividend: 11/15/2024
• Today: 11/20/2024
• Dividend Payable: 11/29/2024
• Next Earnings (Estimated): 1/29/2025
• Fiscal Year End: 9/30/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Drugs, proprietaries, & sundries
• Sub-Industry: Health Care Distributors
• Current Symbol: NYSE:COR
• CUSIP: 03073E10
• CIK: 1140859
• Web: www.amerisourcebergen.com
• Phone: (610) 727-7000
• Fax: 800-640-5221
• Employees: 46,000
• Year Founded: 2001

Price Target and Rating

• Average Stock Price Target: $271.20
• High Stock Price Target: $292.00
• Low Stock Price Target: $224.00
• Potential Upside/Downside: +11.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.73
• Research Coverage: 11 Analysts

Profitability

• EPS (Most Recent Fiscal Year): $7.51
• Trailing P/E Ratio: 32.38
• Forward P/E Ratio: 16.29
• P/E Growth: 1.6
• Net Income: $1.51 billion
• Net Margins: 0.51%
• Pretax Margin: 0.68%
• Return on Equity: 266.62%
• Return on Assets: 4.20%

Debt

• Debt-to-Equity Ratio: 4.84
• Current Ratio: 0.88
• Quick Ratio: 0.53

Sales & Book Value

• Annual Sales: $638.56 million
• Price / Sales: 75.05
• Cash Flow: $21.91 per share
• Price / Cash Flow: 11.10
• Book Value: $3.99 per share
• Price / Book: 60.95

Miscellaneous

• Outstanding Shares: 197,047,000
• Free Float: 165,914,000
• Market Cap: $47.92 billion
• Optionable: Optionable
• Beta: 0.44